Clinical Trials Pipeline & In-Development

PB-718

also known as: PB718

PegBio's dual GLP-1 / GLP-2 agonist — an unusual combination targeting both the incretin axis and intestinal mucosal trophic signaling; Phase 2 in T2DM and NAFLD.

A long-acting dual GLP-1 / GLP-2 receptor agonist peptide developed by PegBio (Suzhou, China), in Phase 2 for type 2 diabetes and non-alcoholic fatty liver disease; an unusual dual combination that adds GLP-2 (intestinal mucosal trophic) signaling to standard GLP-1 incretin agonism, with the pharmacological rationale of protecting the intestinal barrier against GLP-1-driven GI side effects while adding direct intestinal-growth benefit.

Mechanism of action

Dual agonism at GLP-1 and GLP-2 receptors. GLP-1: standard incretin effects. GLP-2: intestinotrophic signaling — enterocyte proliferation, villous growth, tight-junction integrity — which in theory mitigates GLP-1-related GI inflammation and preserves intestinal barrier function.

Primary uses

Type 2 diabetes mellitus (Phase 2)
NAFLD/MASLD (Phase 2)

Typical dosing

once weekly (subcutaneous)

Phase 2 doses not publicly finalized.

Regulatory status

Not approved. Phase 2 in China for type 2 diabetes and NAFLD.

References

[manufacturer] PegBio Co., Ltd. Pipeline disclosures — PB-718 dual GLP-1/GLP-2 agonist.

Related peptides

Semaglutide

A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

Teduglutide

FDA-approved GLP-2 analog (Gattex/Revestive, 2012) for short-bowel syndrome — the first disease-modifying treatment for SBS, reducing parenteral nutrition dependence by promoting intestinal mucosal growth.

Apraglutide

Ironwood's weekly GLP-2 analog for short-bowel syndrome — STARS Phase 3 positive (2024), NDA submitted to FDA 2025; potentially the first once-weekly SBS therapy and a meaningful improvement over teduglutide's daily dosing.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.